IBB News and Press, iShares Biotechnology ETF From 11/04/22

Summary In the healthcare provider space, nursing expense is the largest component of salaries, wages, and benefits. Barring another disruptive COVID surge, however, we believe the market for nurses is now coming back into balance. If the reduction in contract labor expense co...

Summary Attached to the new US Inflation Reduction Act is a multipronged mandate on pharmaceutical companies to limit or lower drug prices. DNA sequencing has especially turbocharged pharmaceutical research, and the cost to use it has steadily fallen. The new law doesn’...

Summary Energy sector volatility and surging oil prices have sharply boosted interest in energy trading this year. Clients can also obtain relative value, or alpha, by rotating between outperforming and underperforming sectors underlying a broad index, according to Woolman. Th...

Summary Persistent inflation spurred the US Federal Reserve to raise interest rates aggressively in the third quarter, with 0.75% hikes in both July and September. Earnings estimates for equities had continued to climb during the early part of the year and only started to moderate...

Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...

Summary The Health Care sector and Biotech niche have both been interesting sources of relative market strength in recent months; one defensive, one more risk-on. 10x Genomics was a massive winner around the Covid-19 pandemic, but an improving health situation around the world pos...

Summary The private sector balance increased by over $349+ billion in September 2022. The shock change is the apparent total collapse of bank credit creation which is only a tiny $2B this last month. The seasonal pattern is trending back upwards into the end-of-year holiday se...

Summary Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach. Biotechs benefit if a...

Summary The European Commission's antitrust accusation against Teva is poorly timed. Teva's selling momentum could continue from here. Teva performing better than biotechnology and pharmaceutical sector. When Teva Pharmaceutical ( TEVA ) responded positively after it...

Summary Galapagos has had a new CEO since April 2022. The company's new strategy is taking shape with some research programs scrapped and small assets acquired. Jyseleca is growing rapidly and has a way to go. Meanwhile, Galapagos trades at a sizeable discount to cash. ...